INTRA-CELLULAR THERAPIES INC (ITCI) Stock Price & Overview
NASDAQ:ITCI • US46116X1019
Current stock price
The current stock price of ITCI is 131.87 USD. Today ITCI is down by -0.04%. In the past month the price increased by 0.48%. In the past year, price increased by 92.68%.
ITCI Key Statistics
- Market Cap
- 14.047B
- P/E
- N/A
- Fwd P/E
- 660.59
- EPS (TTM)
- -0.73
- Dividend Yield
- N/A
ITCI Stock Performance
ITCI Stock Chart
ITCI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ITCI. When comparing the yearly performance of all stocks, ITCI is one of the better performing stocks in the market, outperforming 98.16% of all stocks.
ITCI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ITCI. No worries on liquidiy or solvency for ITCI as it has an excellent financial health rating, but there are worries on the profitability.
ITCI Earnings
On February 21, 2025 ITCI reported an EPS of -0.16 and a revenue of 199.22M. The company missed EPS expectations (-40.63% surprise) and beat revenue expectations (1% surprise).
ITCI Forecast & Estimates
18 analysts have analysed ITCI and the average price target is 133.21 USD. This implies a price increase of 1.02% is expected in the next year compared to the current price of 131.87.
For the next year, analysts expect an EPS growth of 127.35% and a revenue growth 40.33% for ITCI
ITCI Groups
Sector & Classification
ITCI Financial Highlights
Over the last trailing twelve months ITCI reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.46% | ||
| ROE | -6.5% | ||
| Debt/Equity | 0 |
ITCI Ownership
ITCI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.18 | 921.899B | ||
| JNJ | JOHNSON & JOHNSON | 20.74 | 583.292B | ||
| MRK | MERCK & CO. INC. | 22.34 | 286.575B | ||
| PFE | PFIZER INC | 8.9 | 152.733B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.33 | 120.05B | ||
| ZTS | ZOETIS INC | 16.34 | 48.739B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.83 | 26.461B | ||
| VTRS | VIATRIS INC | 5.39 | 15.889B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.81 | 11.276B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.883B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.361B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.698B | ||
| LGND | LIGAND PHARMACEUTICALS | 23.9 | 4.217B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ITCI
Company Profile
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 860 full-time employees. The company went IPO on 2014-01-31. The firm leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Company Info
IPO: 2014-01-31
INTRA-CELLULAR THERAPIES INC
135 Route 202/206, Suite 6
Bedminster NEW JERSEY 10016 US
CEO: Sharon Mates
Employees: 610
Phone: 16464409333
INTRA-CELLULAR THERAPIES INC / ITCI FAQ
Can you describe the business of INTRA-CELLULAR THERAPIES INC?
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 860 full-time employees. The company went IPO on 2014-01-31. The firm leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
What is the stock price of INTRA-CELLULAR THERAPIES INC today?
The current stock price of ITCI is 131.87 USD. The price decreased by -0.04% in the last trading session.
What is the dividend status of INTRA-CELLULAR THERAPIES INC?
ITCI does not pay a dividend.
What is the ChartMill rating of INTRA-CELLULAR THERAPIES INC stock?
ITCI has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Where is INTRA-CELLULAR THERAPIES INC (ITCI) stock traded?
ITCI stock is listed on the Nasdaq exchange.
What is the employee count for ITCI stock?
INTRA-CELLULAR THERAPIES INC (ITCI) currently has 610 employees.